BCR-ABL Tyrosine Kinase Activity Regulates the Expression of Multiple Genes Implicated in the Pathogenesis of Chronic Myeloid Leukemia. Oct The therapeutic armamentarium for chronic myeloid leukaemia ( CML ) comprises mainly tyrosine kinase inhibitors (TKIs), with several agents . Imatinib produces acceptable . This review focuses on tyrosine kinases that have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leukemia and . Jun Targeted Therapies for Chronic Myeloid Leukemia.
This gene makes a protein, BCR-ABL, which causes CML cells to grow and reproduce out of control. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard treatment for CML. Since then, several other tyrosine kinase inhibitors (TKIs) have been . Explain the significant role that tyrosine kinase plays in signal transduction.
In contrast to the situation in CML , in which one gene mutation drives cancer . Jump to The evolving CML treatment landscape - BCR-ABLTKIs for the treatment of CML -CP.